HIV Infections, Lymphoma, Non-Hodgkin
Conditions
Keywords
Mitoxantrone, Lymphoma, Large-Cell, Etoposide, Acquired Immunodeficiency Syndrome
Brief summary
To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
Interventions
DRUGMitoxantrone hydrochloride
DRUGEtoposide
Sponsors
Lederle Laboratories
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must have the following: * Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of AIDS by the CDC criteria. * Diagnosis by pathological examination of large cell or immunoblastic lymphoma within measurable or evaluable disease. * Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study. * Signed written informed consent.
Exclusion criteria
Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks. * Stage IE Central Nervous System lymphomas. Patients with the following are excluded: * More than one previous treatment for lymphoma. * Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks. * Conditions that preclude obtaining an informed consent. * Not accessible for scheduled treatment visits or follow-up. * Stage IE Central Nervous System (CNS) lymphomas. Prior Medication: Excluded within 2 weeks of study entry: * Zidovudine. * Excluded: * Doxorubicin dosing = or \> 300 mg/m2. Prior Treatment: Excluded: * Received more than one previous treatment regimen for lymphoma. Required: * Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.
Countries
United States
Outcome results
None listed